NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced a collaboration with Mayo Clinic to support a newly funded research program evaluating a novel treatment approach for pediatric diffuse midline glioma (DMG), one of the most aggressive childhood brain cancers. The program is supported by a grant from the Children's Cancer Research Fund (CCRF) awarded to Mayo Clinic investigators Dr. David Daniels and Dr. Liang Zhang.
The research aims to address a key challenge in treating malignant brain tumors: achieving and maintaining therapeutic drug concentrations within the tumor. While convection-enhanced delivery (CED) allows drugs to bypass the blood-brain barrier through direct intracranial infusion, therapeutic benefit can be limited by rapid drug clearance. The Mayo Clinic team will evaluate a combination therapy strategy designed to enhance intratumoral drug retention by modulating drug efflux mechanisms, with the goal of prolonging therapeutic exposure after localized delivery. The project will begin with large animal studies and may expand to human studies if successful.
The study will utilize NeuroOne's investigational drug delivery neural device technology, which combines precision intracranial drug delivery with simultaneous neural recording. This integrated approach is designed to enable targeted therapy while providing real-time physiologic monitoring throughout treatment, offering insights into both drug delivery and its effects on the surrounding neural environment.
David Wambeke, Chief Business Officer of NeuroOne, stated, "This collaboration with Mayo Clinic represents another important milestone in the continued expansion of our drug delivery platform. We believe our technology has the potential to become an enabling platform for targeted intracranial therapies by combining precision drug delivery with real-time neural recording. We are honored to support Mayo Clinic's efforts to develop new treatment options for children facing these devastating brain tumors."
The CCRF award marks an important step in advancing this therapeutic approach toward investigational clinical evaluation. The collaboration expands NeuroOne's growing portfolio of drug delivery initiatives and reflects increasing interest from academic investigators and biopharmaceutical companies in the company's drug delivery platform. NeuroOne markets a minimally invasive electrode technology platform with four FDA-cleared product families, including Evo® Cortical Electrodes and the OneRF® Ablation System, and is engaged in research and development for drug delivery and other programs. More information is available at nmtc1.com.
